Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 6:04 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TEVA 16.98 +0.17(1.01%)
Will TEVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Other News for TEVA
Hims & Hers appoints former Novo Nordisk president to board
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Teva's Migraine Treatment Found Effective For Children As Young As 6
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
Axsome Therapeutics price target lowered by $2 at BofA, here's why